ReviewJournal of gastroenterology2016
Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases.
Review in Journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 25 citations in OpenAlex.
- Different pattern of stool and plasma gastrointestinal damage biomarkers during primary and chronic HIV infection.PloS one · 2019Trial
- Increased Intestinal Inflammation and Permeability in Glaucoma.Journal of inflammation research · 2024Article
- Identifying predictors of clinical outcomes using the projection-predictive feature selection-a proof of concept on the example of Crohn's disease.Frontiers in pediatrics · 2023Article
- Fecal S100A12 is associated with future hospitalization and step-up of medical treatment in patients with Crohn's disease in clinical remission: a pilot study.Intestinal research · 2022Article
- Serum biomarkers confirming stable remission in inflammatory bowel disease.Scientific reports · 2021Article
- Biomarkers of Crohn's Disease to Support the Development of New Therapeutic Interventions.Inflammatory bowel diseases · 2020Article
- Biomarkers Predictive of Response to Thiopurine Therapy in Inflammatory Bowel Disease.Frontiers in medicine · 2020Review
- Inflammatory Bowel Disease in Childhood and Adolescence.Deutsches Arzteblatt international · 2017Review
- [Tapering and termination of immunosuppressive treatment in spondyloarthritides (including psoriatic arthritis)].Zeitschrift fur Rheumatologie · 2017Review
- Observational
- Article
- B Cell-Activating Factor (BAFF) in Inflammatory Bowel Disease: BAFFling No Longer?Digestive diseases and sciences · 2016Article
- Comparisons between myeloperoxidase, lactoferrin, calprotectin and lipocalin-2, as fecal biomarkers of intestinal inflammation in malnourished children.Journal of translational science · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with diagnosed inflammatory bowel disease (IBD) will commonly experience a clinical relapse in spite of a prolonged therapy-induced period of clinical remission. The current methods of assessing subclinical levels of low-grade inflammation which predispose patients to relapse are not optimal when considering both cost and patient comfort. Over the past few decades, much investigation has discovered that proteins such as calprotectin that are released from inflammatory cells are capable of indicating disease activity. Along with C-reactive protein and erythrocyte sedimentation rate, calprotectin has now become part of the current methodology for assessing IBD activity. More recently, research has identified that other fecal and serum biomarkers such as lactoferrin, S100A12, GM-CSF autoantibodies, α1-antitrypsin, eosinophil-derived proteins, and cytokine concentrations have variable degrees of utility in monitoring gastrointestinal tract inflammation. In order to provide direction toward novel methods of predicting relapse in IBD, we provide an up-to-date review of these biomarkers and their potential utility in the prediction of clinical relapse, given their observed activities during various stages of clinical remission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.